MX2021000796A - Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida. - Google Patents

Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida.

Info

Publication number
MX2021000796A
MX2021000796A MX2021000796A MX2021000796A MX2021000796A MX 2021000796 A MX2021000796 A MX 2021000796A MX 2021000796 A MX2021000796 A MX 2021000796A MX 2021000796 A MX2021000796 A MX 2021000796A MX 2021000796 A MX2021000796 A MX 2021000796A
Authority
MX
Mexico
Prior art keywords
ultra
compositions
therapeutically active
active particles
rapid freezing
Prior art date
Application number
MX2021000796A
Other languages
English (en)
Inventor
Iii Robert O Williams
Chaeho Moon
Alan B Watts
John J Koleng
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2021000796A publication Critical patent/MX2021000796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las composiciones farmacéuticas que contienen menos del 10% de un excipiente y se presentan como nanoagregados se describen en la presente. Se ha demostrado que estas composiciones farmacéuticas presentan propiedades mejoradas tales como la mejora de la aerosolizabilidad y el comportamiento aerodinámico. También se proporcionan en la presente métodos para preparar las composiciones farmacéuticas descritas en la presente y uso de los mismos.
MX2021000796A 2018-07-24 2019-07-24 Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida. MX2021000796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862702674P 2018-07-24 2018-07-24
PCT/US2019/043202 WO2020023614A1 (en) 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing

Publications (1)

Publication Number Publication Date
MX2021000796A true MX2021000796A (es) 2021-06-15

Family

ID=69181152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000796A MX2021000796A (es) 2018-07-24 2019-07-24 Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida.

Country Status (12)

Country Link
US (1) US20210338671A1 (es)
EP (1) EP3827260A4 (es)
JP (1) JP2021530551A (es)
KR (1) KR20210038583A (es)
CN (1) CN112673257A (es)
AU (1) AU2019311086A1 (es)
BR (1) BR112021001290A2 (es)
CA (1) CA3106618A1 (es)
EA (1) EA202190331A1 (es)
IL (1) IL280342A (es)
MX (1) MX2021000796A (es)
WO (1) WO2020023614A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN113398079B (zh) * 2020-03-16 2024-01-19 鲁南制药集团股份有限公司 一种注射用氟达拉滨冻干粉
MX2023002465A (es) * 2020-09-03 2023-03-23 Philip Morris Products Sa Composiciones en polvo activas de baja higroscopicidad secadas por congelacion.
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
JP2024510209A (ja) * 2021-03-12 2024-03-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 懸濁液ベースの薄膜凍結を用いて乾燥粉末を調製するための方法
US20220321859A1 (en) 2021-03-25 2022-10-06 Korea Advanced Institute Of Science And Technology Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof
CN113484469B (zh) * 2021-06-30 2022-11-18 中国科学院青海盐湖研究所 水合盐体系相变储能材料纳米尺度相分离的原位表征方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US20180147161A1 (en) * 2015-05-01 2018-05-31 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions

Also Published As

Publication number Publication date
CA3106618A1 (en) 2020-01-30
CN112673257A (zh) 2021-04-16
KR20210038583A (ko) 2021-04-07
EP3827260A4 (en) 2022-05-04
WO2020023614A1 (en) 2020-01-30
EP3827260A1 (en) 2021-06-02
JP2021530551A (ja) 2021-11-11
AU2019311086A1 (en) 2021-02-04
US20210338671A1 (en) 2021-11-04
IL280342A (en) 2021-03-25
BR112021001290A2 (pt) 2021-04-27
EA202190331A1 (ru) 2021-06-17

Similar Documents

Publication Publication Date Title
MX2021000796A (es) Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida.
PH12020551572A1 (en) Heterocyclic compounds as immunomodulators
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
WO2020160193A3 (en) Compounds and uses thereof
PH12018501340A1 (en) Heterocyclic compounds as immunomodulators
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
EP3693369A3 (en) Bromodomain inhibitors
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
WO2017214170A3 (en) Baff-r antibodies and uses thereof
TN2017000031A1 (en) Imidazopyridazine compounds
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
NZ728914A (en) Aripiprazole prodrug compositions
PH12020550133A1 (en) Crystal forms of immunomodulators
MX2019009341A (es) Composiciones lubricantes para el flujo de semillas y usos de estas.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2016013589A (es) Composiciones que comprenden derivados de osteopontina para la inhibicion del crecimiento de pelo.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
WO2016116882A3 (en) Novel compositions of carfilzomib